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Background: Sickle cell disease (SCD) is the most frequent hemoglobinopathy worldwide but remains a rare blood
disorder in most western countries. Recommendations for standard of care have been produced in the United
States, the United Kingdom and France, where this disease is relatively frequent because of earlier immigration
from Africa. These recommendations have changed the clinical course of SCD but can be difficult to apply in other
contexts. The Italian Association of Pediatric Hematology Oncology (AIEOP) decided to develop a common national
response to the rising number of SCD patients in Italy with the following objectives: 1) to create a national working
group focused on pediatric SCD, and 2) to develop tailored guidelines for the management of SCD that could be
accessed and practiced by those involved in the care of children with SCD in Italy.
Methods: Guidelines, adapted to the Italian social context and health system, were developed by 22 pediatric
hematologists representing 54 AIEOP centers across Italy. The group met five times for a total of 128 hours in
22 months; documents and opinions were circulated via web.
Results: Recommendations regarding the prevention and treatment of the most relevant complications of SCD in
childhood adapted to the Italian context and health system were produced.
For each topic, a pathway of diagnosis and care is detailed, and a selection of health management issues crucial to
Italy or different from other countries is described (i.e., use of alternatives for infection prophylaxis because of the
lack of oral penicillin in Italy).
Conclusions: Creating a network of physicians involved in the day-to-day care of children with SCD is feasible in a
country where it remains rare. Providing hematologists, primary and secondary care physicians, and caregivers
across the country with web-based guidelines for the management of SCD tailored to the Italian context is the first
step in building a sustainable response to a rare but emerging childhood blood disorder and in implementing the
World Health Organization’s suggestion “to design (and) implement … comprehensive national integrated
programs for the prevention and management of SCD".
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Sickle cell disease (SCD) is the most common genetic dis-
order worldwide. Every year, an average of 300,000 children
are born with sickle syndromes, and the prevalence of sickle
cell among newborns ranges from 0.1/1000 in non-
endemic countries to 20/1000 in several parts of Africa [1].
The United Nations and the World Health Organization
(WHO) recognize inherited hemoglobin (Hb) disorders as a
global public health problem [2,3], and the WHO has urged
the National Health Systems “to design, implement and
reinforce … comprehensive national integrated programs
for the prevention and management of SCD” [2]. In fact,
although 19–27% of the African population carries the
sickle cell allele, migration movements have brought SCD
patients from high-frequency regions to Europe. Therefore,
SCD has become the paradigm of immigration hematology
in Europe [4]. Although considered a rare disease because
of its global frequency in the 28 countries of the European
Union, SCD is the most prevalent genetic disease in France
[5] and the United Kingdom [6], and its frequency is stead-
ily rising in many other countries of central and southern
Europe [4,7,8]. The European Union considers SCD a rare
disease and sponsored the European Network on Rare and
Congenital Anemias (known as ENERCA) to facilitate col-
laboration among clinicians in the field of rare anemias,
including SCD [9]. Several countries have developed a spe-
cific response to meet the needs of the growing number of
patients with SCD. In France, national guidelines have
been produced [10] and reference centers have been desig-
nated by the Health Ministry that offer focused services
for SCD [11]; a newborn screening was performed at na-
tional level since 2000 for all newborns defined as being
“at risk” for SCD based on ethnic origin [12]. In the
United Kingdom, the development of national guidelines
and the realization of a universal newborn screening pro-
gram have been the first steps undertaken to offer special-
ized care [6]. Belgium and the Netherlands have also
organized clinical services and newborn screening for he-
moglobinopathies and are conducting careful investiga-
tions [13,14].
Although the experience gained from the United
States and the above mentioned European countries has
forged a pathway for those involved in the care of pa-
tients with SCD, public health issues and policies associ-
ated with SCD need to be tailored according to each
country’s availability of health care and the characteris-
tics of the affected population [15-17]. Italy does not
have a national hemoglobinopathy newborn screening
program, and for many years, pediatric hematology ser-
vices have focused primarily on beta thalassemia. A net-
work for treatment and care of thalassemia patients has
been developed in Italy since the 1970s, involving centers in
the central and southern parts of the country, where the
majority of thalassemia patients live. Moreover, guidelinesfor the management of thalassemia were implemented and
are well known by physicians across the country. National
public health interventions for prevention and screening of
thalassemia conditions are widespread; sound research has
been conducted, and patient associations continuously raise
awareness of thalassemia and advocate for support.
In contrast, SCD was historically a disease limited to the
population of Sicily where the sickle cell allele frequency is
2–13% [18]. Recent immigration from Africa, South
America, and the Balkans, mainly into the northern regions,
has changed the geographic profile of SCD [7,19,20], how-
ever, with an increase of new diagnoses in the north, mak-
ing this disease a more widespread public health issue [21].
Although the number of affected children has steadily in-
creased over the last decade [7,19-21], by the end of 2008,
centers focused on the care of SCD were still rare, and clin-
ical counseling for SCD was performed either by hematolo-
gists trained for thalassemia and not for SCD, or by
pediatricians. No common policy of diagnosis and treat-
ment had been developed, and the treatment was mainly
case directed or locally directed. Moreover, the majority of
SCD patients were African immigrants, living in northern
Italy where hemoglobinopathies were less known.
The Italian Association of Pediatric Hematology On-
cology (AIEOP) has a membership of all 54 Pediatric
Hematology Oncology Centers across Italy and has
existed since the 1970s (the website is www.aieop.org).
It has developed common protocols and a database for
children with cancer and non-oncologic diseases. The
AIEOP Red Cell Group, involved in non-oncologic
hematology, decided to develop a common national
response to the rising number of SCD patients. Its ob-
jectives are creating a national working group focused on
pediatric SCD and developing tailored guidelines for the
management of children with SCD in Italy that could be
accessed and practiced by all those involved in the care of
the pediatric SCD population in the country.
We thought that creating a network of physicians in-
volved in the day-to-day care of children with SCD and
providing physicians and caregivers across the country
with guidelines for the management of SCD tailored to
our specific Italian context were the first steps in build-
ing a sustainable response to this newly more wide-
spread disorder. The purpose of this paper is not to
detail the guidelines but to describe the pathway chosen
by the AIEOP Group to address a rare but increasingly
prevalent blood disorder in Italy and summarize the rec-
ommendations that were critical for our specific health
system and national context.
Methods
All 54 AIEOP centers were invited to participate in
the SCD Working Group. Issues to be addressed in the
guidelines were chosen by the group considering the
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clinical issues in pediatric SCD [6,22,23]; every topic was
developed by a subgroup in a single document. Each
document included a brief description of the state-of-the
-art recommendations with ABC ranking of strength of
the evidence and references. Statements were based on
literature evidence; when available evidence was not suf-
ficient, the working group developed specific recommen-
dations, based on expert author opinion or existing
guidelines, and such statements were clearly presented
as opinion. Each document was revised by the entire
group and modified accordingly after exhaustive discus-
sion. Four members of the group completed the internal
revision of the final document, and external revision was
performed by three Italian expert pediatric hematologists
and one patient association.
Results and discussion
The SCD working group consisted of 22 pediatric hema-
tologists from 14 centers (north 9, central 1, south 4),
who met five times during 20 months from 2008 to
2010, for a total of 120 hours of meetings. One final
8-hour meeting was held in 2012 for definitive revision
and approval of the document. Specific characteristics of
our health system were taken into consideration in writ-
ing the guidelines. (see below List of Characteristics of
the Italian context).
Characteristics of the Italian context
No national hemoglobinopathies newborn screening
program
National free health care; direct primary, secondary,
and tertiary pediatric care for children
Regulation of health care provided by regional health
care systems with regional differences and disparities in
health care facilities and resources across the country
Specialized care delivered on a hospital-based model
and not on a medical home-based model
Free vaccinations with vaccination campaigns
conducted on regional basis
Care for sickle cell patients delivered in pediatric
hematology oncology centers among oncology patients
→ lack of teams dedicated to sickle cell patients
→ management of pain crisis in the emergency room
No availability of oral penicillin in the country
No availability of pediatric transcranial Doppler
services, but an adult stroke network exists in the
country
Recommendations
The guidelines, written in Italian, consist of 27 chapters
and 242 recommendations and explore the milestones of
SCD diagnosis, prevention, and treatment, tailoring
them to the Italian public health system organizationand drug availability. Recommendations that were con-
sidered more critical in our context and deserved exten-
sive discussion are described below.
Neonatal screening
Universal neonatal screening, or at least targeted screen-
ing, is recommended. A comprehensive program for glo-
bal prix en charge should enroll children after the
neonatal diagnosis, with adequate health education for
parents, implementation of preventive and therapeutic
measures, and appropriate follow-up. We are aware that
for the present, only two pilot selective screenings are
being conducted in Italy, organized on a local basis (in
the Region of Friuli Venezia Giulia and in the city of
Modena).
Amoxicillin prophylaxis and vaccinations
Since its introduction for children with SCD, penicillin
prophylaxis has resulted in a large reduction of invasive
pneumococcal infections; therefore, it is recommended
starting at 2 months of age (Table 1). In Italy, the oral for-
mulation of penicillin is not available, and a depot i.m.
formulation is difficult to find; therefore, the group made
an effort to search the literature and to elaborate alterna-
tive prophylaxis options. The recommendation for Italy
is to use amoxicillin or, as an alternative, a macrolide
(Table 2). Pneumococcus immunization with both conju-
gated (PVC13) and polysaccharidic (Pneumo23) vaccine
is recommended. Annual influenza vaccination is also
recommended to reduce possible severe complications
[24].
Management of painful vaso-occlusive crisis (VOC)
VOCs are the hallmark of SCD, and extensive literature
has demonstrated that the optimal management of
VOC is in hematology day care centers [31,32]. In Italy,
SCD patients with VOC are usually admitted to the
general emergency room (ER), however; therefore, the
guidelines emphasize the need to train ER personnel in
the management of VOC. Generally, pediatricians are
not comfortable with the use of analgesics, especially
opioids; consequently, the guidelines detail each drug,
including the safety profile and practical dilution mo-
dality, to make their use easier even for pediatricians
who are not familiar with them. Table 3 lists the differ-
ential diagnoses of VOC and acute emergencies to ease
patient care for ER personnel who are not familiar with
SCD patients.
A visual analogue scale (VAS) or a numerical scale is
always recommended for pain evaluation. The treatment
of pain is to be established as quickly as possible, within
30 minutes from arrival in the ER, even before the iden-
tification of the cause or the possible differential diagno-
ses. The choice of the drug/s to be used must take into
Table 1 Recommendation for penicillin prophylaxis
Recommendation Evidence
Penicillin prophylaxis is strongly recommended for all children with SCD (homozygous SS, SC disease, Sβ °thalassemia) up to 6
years of age.
A
Penicillin prophylaxis is recommended in subjects with genotype SC, even if no clear study demonstrates its benefit in this form of SCD. C
Prophylaxis with oral penicillin should be done, but because it is not available in Italy, the alternative drugs described in Table 3 or the
parenteral formulation can be used.
C
Antibiotic prophylaxis should begin between the second and third months of life in children who received a neonatal diagnosis of SCD. A
In Italy, newborn screening is not provided; therefore, the pediatrician who cares for an infant at high risk of SCD (geographic origin,
family history of hemoglobinopathy) should test the infant for the presence of the disease, even in the absence of symptoms, and
prescribe prophylactic penicillin by the third month.
B
It is controversial whether it is necessary to continue penicillin prophylaxis beyond 5 years of age, although it is certainly more prudent to
recommend the continuation of prophylaxis throughout life.
C
Long-term prophylactic therapy causes problems of adherence, which may be limited by clear information about the benefits of
prophylaxis, the risks of a low adherence, and the involvement of parents in the management of disease and care of the child.
C
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been used at home. The primary objective is to reduce the
initial VAS score by 50%. Pain revaluation should be
performed every 30 minutes until complete resolution.
Children should receive analgesics at fixed intervals with
“rescue” doses for pain that occurs in the interval between
doses. The interval between doses should be determined in
accordance with the intensity of pain and the duration of
the analgesic effect of the drug in question. Acetaminophen,
ibuprofen, ketorolac, codeine, and morphine analgesics are
the recommended drugs for the treatment of pain in
children.
Management of fever and infections
The management of the febrile child was the subject of in-
tense discussion in the working group because of the dis-
parities in health care facilities and availability of ER staff
between northern and southern Italy and because of the
many isolated and rural areas lying long distances from
health centers in certain parts of the country. The decision
was finally to define the presence of fever in a child
with SCD as a medical emergency (“All those who manage
children with SCD—pediatricians, hematologists, medicalTable 2 Alternative drugs for antibiotic prophylaxis
Proposing group Age Recom
Antib
Working Party of the British Committee for <5 y Amox
Standards in Haematology Clinical 5–14 y Amox
Haematology Task Force [25,26] >14 y Amox
The Hospital for Sick Children, Toronto [27-29] 2–6 months Trimet
6 months–5 y Amox
>5 y Amox
Australasian Society for Infectious Diseases [30] 2 months–2 y Amox
Adults Amoxemergency staff, parents—should be aware that fever is a
medical emergency which must be assessed and treated in
the shortest possible time”), but to suggest different path-
ways of diagnosis and care between children at high risk of
severe infection and at standard risk of severe infection
(Table 4). Children at high risk of severe infection should
be admitted; children at standard risk of severe infection
should receive a dose of ceftriaxone and at least 3 hours of
observation. The possible active involvement of the child’s
pediatrician is considered.
Acute chest syndrome (ACS)
ACS is defined as the appearance of a new infiltrate on
chest X-ray in association with at least one of the following:
fever, dyspnea, chest pain, or desaturation. ACS is the sec-
ond leading cause of hospitalization for patients with SCD
and one of the leading causes of mortality. It is a potentially
severe manifestation of SCD, and the patient therefore
should always be hospitalized. The useful therapeutic mea-
sures are administration of O2, hydration, analgesia, early
transfusion, and bronchodilators (especially if there is
wheezing). Antibiotic therapy is always indicated. As a
first choice, the ceftriaxone (or cefotaxime) +macrolide ismendation for antibiotic prophylaxis
iotic Dose Frequency
icillin 10 mg/kg/d Once a day
icillin 125 mg/d Once a day
icillin 250–500 mg/d Once a day
hoprim/sulfamethoxazole TMP 5 mg SMX 25 mg/kg Once a day
icillin 20 mg/kg/d Twice a day
icillin 250 mg/day Twice a day
icillin 20 mg/kg/d Once a day
(max 250 mg/d) Once a day
icillin 250 mg/d
Table 3 Differential diagnosis between vaso-occlusive crisis and other acute emergencies
Site of pain Differential diagnosis Exams to consider




Neck/throat Meningitis Lumbar puncture
Torticollis/stiff neck Throat swab
Pharyngitis/tonsillitis Esophago gastro duodenal endoscopy
Esophagitis/gastroesophageal reflux
Thorax Acute chest syndrome/reactive airway disease/asthma Thorax X-ray
Osteochondritis ECG
Heart (myocardial infarction) Esophago gastro duodenal endoscopy
Gastroesophageal reflux




Gallbladder stones Throat swab






Limping without pain MRI, MRA
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staphylococcal antibiotic. The use of “incentive spirom-
etry” is indicated and is also effective in preventing the
onset of ACS in all conditions of reduced thoracic mo-
bility (chest pain crisis, immobilization in bed, etc.).
There should be a timely transfer to the Intensive Care
Unit (ICU) with sudden clinical worsening, requiring
ventilatory support. The use of steroids is at present
controversial, and the use of nitric oxide is still experi-
mental. Because of the increasing recognition of this
condition as a risk factor of disease severity in SCD,
wheezing and asthma must be recognized and treated,
as well as allergies for wheezing prevention.
Transcranial Doppler (TCD)
Early TCD screening and transfusion programs applied
in patients with abnormal TCD really allows to signifi-
cantly reduce stroke risk from 11 to less than 2% by age
18 and should be systematically offered to all children
with SCD [33-35].
Because of the deficiency of this procedure in the
Italian context, a particular emphasis has been given tothis chapter, highlighting the difficulties other countries
have faced in setting up a TCD program (lack of trained
radiologists, missed appointments, education of patients
and their parents, training of providers-pediatricians,
hematologists, pediatric radiologists, service organization
and patients’ access). In fact, in the USA, despite incon-
trovertible evidence of the value of screening for stroke
risk, the adherence to the TCD surveillance programs is
still less than 50% [36]. The results of a nationwide sur-
vey revealed poor compliance because of several obsta-
cles, with the most frequent problems being poor
patient attendance (as a result of the distance to the vas-
cular screening laboratory) and the lack of personnel
trained to perform TCD. The large majority of surveyed
hematologists experienced difficulty in obtaining TCD
assessment for their patients [37]. McCarville et al. [38]
highlighted the importance of a comprehensive screen-
ing program in a single-center study in which the center
achieved a 99% screening rate of the at-risk population
in 3 years. The success of this comprehensive program
relied on investing resources in personnel training and
patient education.
Table 4 Clinical features useful for assessing the risk of severe infection in febrile patients
High risk Low risk
(One or more of the following) (All of the following)
Age < 3 years of age > 3 years of age
Health conditions Compromised Stable
Temperature >40°C >38.5°C and <40°C
Refill Increased Normal
Hydration status Dehydration and/or reduced fluid assumption and/or oliguria Normal
Acute chest syndrome Yes No
History of sepsis or severe infection Yes No
Allergy to penicillin and cephalosporin Yes No
Blood pressure Hypotension Normal
Hemoglobin <5 g/dl <2 g/dl from baseline
White blood cells >30 × 103/mm3 or <5 × 103/mm3 Normal
Platelets <100 × 103/mm3 Normal
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2 to 16 at least once a year It must be performed
according to a specific protocol by trained staff to obtain
reliable and reproducible results. If TCD is normal, a re-
peat screen is recommended after 12 months; if it is be-
tween 170–200 cm/s (conditional), it should be repeated
within 3 months, especially if the child is under age
6 years. In individuals with TCD > 200 cm/s, a second test
should be repeated within 2 months and, if confirmed as
pathological, enrollment in a chronic transfusion program
is recommended. In patients with abnormal TCD, an-
other recommendation is to perform an MRI and MRA
investigation for possible detection of brain injury. If
blood flow is too low (TCD < 70 cm/s) or there is signifi-
cant asymmetry between the two sides or if TCD cannot
be performed, it is necessary to complete alternative neu-
roimaging studies, such as MRI and MRA. TCD imaging
can be used in place of the TCD.Blood transfusion
The issue of blood transfusion has been particularly fo-
cused to clearly differentiate indications for transfusion
in SCD from thalassemia; the risk of alloimmunization
has been stressed because of the lack of African donors
in Italy and the need to avoid alloimmunization as much
as possible (Table 5).
Indications for acute transfusion are acute symptomatic
anemia with clinical signs of heart failure (tachycardia, tach-
ypnea, dyspnea, fatigue) or absolute Hb ≤ 5 g/dl; it should
be considered for a drop in Hb ≥ 2 g/dl from steady state or
acute hepatic or splenic sequestration [1,6]. In this last case,
the values of Hb measured after transfusion are generally
higher than expected; therefore, to prevent heart failure, it
is better to transfuse 3.5 ml/kg of packed red blood cells,equal to half the usual dose [1] and then repeat the transfu-
sion after a few hours. Great care must always be taken to
avoid exceeding 10 g/dl Hb, above which the phenomenon
of hyperviscosity may be dangerous. In severe infection,
sepsis, or meningitis with significant anemia (Hb < 7 g/dl),
blood transfusion should be performed because of the
lower tolerance to anemia in the course of severe infection.
In cases of high levels of Hb and transfusion indication, as
in ACS or stroke, erythrocytapheresis is mandatory.
The indications for chronic transfusion are primary
prevention of stroke in children with abnormal TCD,
secondary prevention of stroke, and chronic heart fail-
ure, although there are no clinical studies that have
shown its effectiveness in children. The goal of a chronic
transfusion program is to maintain HbS level under 30%
and Hb between 9 and 11 g/dl.Iron overload and iron chelation
Iron overload has been a widely discussed topic, consid-
ering the lack of any official indication about its moni-
toring and treatment in SCD. Differences between
thalassemia and SCD in the pattern of iron accumula-
tion and complication rate have been the focus [39-43],
and indications for monitoring, start of treatment, and
drug choice have been addressed. Parameters for moni-
toring of iron overload were considered and specific rec-
ommendations made (Table 6). Recommended criteria
for deciding the start of iron chelation therapy are serum
ferritin level persistently ≥ 1000 ng/ml and transfused
red blood cells ≥ 120 cc/kg (or after 20 transfused units)
and/or a Liver Iron Concentration (LIC) ≥ 5–7 mg/g dw.
Compliance with chelation therapy affects morbidity
and mortality in iron overloaded patients [44,45], so a
drug must be evaluated considering patient satisfaction,
Table 5 Recommendations to decrease the risk of alloimmunization
Recommendations Evidence
Perform a wide erythrocyte antigenic phenotype (ABO, Rh, Kell, Duffy, Kidd, Lewis, Lutheran, P, and MNS) before the first transfusion,
especially if you plan to establish a chronic transfusion program; physicians, health care providers, and the patient or family should have a
copy of the same phenotype.
C
Pre-storage leukodepletion of RBCs is recommended to reduce febrile reactions and complications due to cytokine release. C
All patients who have previously performed red cell transfusions should be periodically checked for alloantibodies (they can cause a
delayed transfusion reaction).
C
Preferably use “fresh” blood (<3 days of life of RBCs) to minimize hypoxia during the procedure and to reduce the consumption of RBCs
in chronically transfused patients while minimizing iron overload.
C
Use blood negative for hemoglobinopathies. Each center must activate a strategy suited to avoid transfusing blood of carriers of
Hemoglobin S.
C
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Deferoxamine is an effective drug with an acceptable
safety profile [46,47], but patient adherence to this ther-
apy is poor because of side effects and difficult route of
administration (subcutaneous infusions over an 8- to 12-
hour period, 5–7 days per week). Deferasirox is an oral
chelator that has shown efficacy and safety in managing
iron overload in SCD [48]. Patients on deferasirox have
higher satisfaction and rate its convenience higher than
patients do for deferoxamine [49], so deferasirox is rap-
idly becoming the standard care.Hydroxyurea (HU)
Because of the reluctance of pediatricians to prescribe HU,
specific indications and the safety profile have been par-
ticularly stressed in the guidelines. The clinical efficacy
and low toxicity of HU have been demonstrated by the
multi-center study HUG-KIDS Phase I/II [50], and re-
cently in the randomized, double-blind, BABYHUG, which
demonstrated the safety and efficacy of HU in “infants”
(mean age 13.6 months) in reducing episodes of dactylitis,
pain, and ACS in a population of patients not selected
according to the clinical severity of the disease. The study
also confirmed the safety of administration in the first few
years of life [51]. Pediatric studies have highlighted
other potential benefits of HU in the prevention of
organ damage, the maintenance of splenic function,
and improved growth [52,53]. It is still unclear what
role HU can have in primary and secondary prevention
of stroke.Table 6 Recommendations for monitoring iron overload
Recommendations
Serum ferritin level could increase during VOC; assessment at steady state is
Serial measurements of serum ferritin and iron intake are recommended befo
LIC (liver iron concentration), measured by magnetic resonance T2* or R2*, S
(magnetic iron detector), all techniques available in Italy, should be assessed
Cardiac iron assessment, measured by magnetic resonance T2*, is recommenConclusion and implications for public health practice
The organization of a national network and the develop-
ment of national guidelines for pediatric SCD in Italy are
the first steps in implementing the WHO suggestion “to
design (and) implement … comprehensive national inte-
grated programs for the prevention and management of
SCD” and to address the two major priorities for the
treatment of SCD, identified by patients in a question-
naire submitted in 2007 by the National Heart Lung and
Blood Institute. One top priority that patients identified
was the development of clear, evidence-based, local
guidelines that they and their physicians could use to en-
sure that they were receiving optimal care, maximizing
appropriate referral to hematologic specialist [54]. The
second priority was appropriate management of pain.
The development of national guidelines targeted to a
specific national context allows addressing both prior-
ities. The organization of the national network and the
diffusion of the locally adapted guidelines in Italy were
followed by several educational events and training
courses on the management of SCD in childhood and
TCD that involved hundreds of primary and secondary
care pediatricians and pediatric hematologists across the
country. Patient empowerment initiatives involving im-
migrant communities have begun to be developed, and
every year the SCD World Day is now celebrated in
most centers with open initiatives.
A better and standardized management of this rela-
tively rare but complex disease implies that health sys-
tems will waste less money to treat acute or chronic
complications and will optimize patient management.Evidence
recommended. C
re starting iron chelation therapy. C
QUID (superconducting quantum interference device), or MID
before starting iron chelation therapy.
C
ded before starting iron chelation therapy. C
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hospitals much more than their peers [7,16,17]. More-
over, SCD is in fifth place among the top 10 diagnoses
with the highest readmission frequency, having the
highest percentage of readmission (79.4%) [55]. The
yearly cost of care for a pediatric patient 1–9 years of
age with SCD is 7948 euro in countries where neonatal
screening allows early diagnosis and comprehensive care
is organized, assuring a holistic approach to health care;
the morbidity and mortality and, therefore, the costs are
much higher in cases of late diagnosis or no access to
SCD specialized centers [16,17,56-60]. A preliminary
single-center experience even in a low-prevalence coun-
try such as Italy has shown that comprehensive special-
ized care for a vulnerable group of immigrant children
with SCD produces lower admission rates and lower use
of the ER [61]. Detailed cost analysis is available for the
USA but scarce for European countries; therefore, re-
search in this field in Europe is needed.
In conclusion, creating a network of physicians in-
volved with the day-to-day care of children with SCD
and providing physicians and caregivers across the coun-
try with guidelines for the management of SCD tailored
to the specific Italian context can be the first steps in
building a sustainable response to a rare but nationally
emerging blood disorder in childhood.
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